AAN 2019 Coverage

Results from a study evaluating the safety and efficacy of suvorexant (Merck) for the treatment of insomnia in patients with mild to moderate Alzheimer disease dementia were presented at the 2019 American Academy of Neurology Annual Meeting. The phase 3 placebo-controlled trial included 277 patients who were randomized to receive either suvorexant 10mg (which could…